Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive save search
B2Gold Announces Positive Exploration Drilling Results from the Antelope Deposit at the Otjikoto Mine in Namibia, Highlighting the Potential to Expand Underground Gold Production through the Early 2030’s
Published: 2024-01-31 (Crawled : 13:00) - globenewswire.com
BTG | $2.61 -1.88% 0.73% 11M
|
Non-Energy Minerals
|
| O: 0.35%
H: 1.06%
C: -1.06%
positive potential results
Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024
Published: 2024-01-31 (Crawled : 13:00) - globenewswire.com
DARE | $0.299 5.77% 5.45% 970K
|
Health Technology
|
| O: -2.16%
H: 8.61%
C: 1.06%
fda company positive bioscience meeting
Agrify Receives Positive Nasdaq Listing Determination
Published: 2024-01-31 (Crawled : 12:30) - globenewswire.com
AGFY | $0.29 -20.55% -25.86% 2.5M
|
|
| O: 13.64%
H: 10.67%
C: -1.35%
nasdaq positive
Novartis delivers strong full year performance, 10% net sales and 18% core operating income growth (cc¹), with margin expansion. Continuing innovation momentum with multiple positive Ph3 readouts
Published: 2024-01-31 (Crawled : 06:00) - globenewswire.com
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -2.04%
H: 0.19%
C: -1.97%
sales year momentum positive innovation novartis growth
Sysco Reports Second Quarter EPS Growth, Driven By Increasing Volumes and Positive Operating Leverage
Published: 2024-01-30 (Crawled : 13:00) - globenewswire.com
SYY | $75.64 0.27% 1.93% 2.1M
|
Distribution Services
|
| O: 0.51%
H: 7.17%
C: 6.98%
positive
Motus GI Holdings Publishes Positive Results from a European Study of the Second Generation Pure-Vu System in Improving Visualization for Colonoscopy in Patients with a History of Poor Bowel Preparation
Published: 2024-01-30 (Crawled : 13:00) - globenewswire.com
MOTS | $0.1735 -46.17% 1.4M
|
Health Technology
|
| O: 14.04%
H: 0.92%
C: -34.86%
positive system results study
Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain
Published: 2024-01-30 (Crawled : 12:30) - biospace.com/
VRTX | News | $393.51 0.1% 0.1% 950K
|
Health Technology
|
| O: -1.34%
H: 4.28%
C: 3.74%
vx-548 positive treatment program results
Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
Published: 2024-01-30 (Crawled : 12:00) - prnewswire.com
ITRM | $1.45 -0.69% -0.69% 57K
|
Health Technology
|
| O: 28.49%
H: 1.74%
C: -31.3%
positive topline sulopenem infections trial therapeutics results
Nuclear Fuels Reports Positive Drill Results from the Kaycee Uranium Project, Wyoming
Published: 2024-01-30 (Crawled : 12:00) - prnewswire.com
EU | $4.37 -3.53% -3.66% 1.5M
|
n/a
|
| O: 0.0%
H: 5.56%
C: 4.67%
nuclear positive uranium results
Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia
Published: 2024-01-30 (Crawled : 12:00) - globenewswire.com
KURA | $17.66 -1.83% -1.87% 1.7M
|
Health Technology
|
| O: -0.54%
H: 23.89%
C: 12.7%
positive leukemia
Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
Published: 2024-01-29 (Crawled : 15:30) - biospace.com/
SRPT | $116.59 -1.1% -1.12% 500K
|
Health Technology
|
| O: 0.06%
H: 3.66%
C: 1.43%
srp-5051 positive therapeutics duchenne study
Palisade Bio Announces Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn’s & Colitis Congress
Published: 2024-01-29 (Crawled : 13:00) - globenewswire.com
PALI | $5.065 -23.26% -30.31% 310K
|
Manufacturing
|
| O: 125.0%
H: 27.35%
C: -17.95%
pali-2108 congress positive preclinical program
ParaZero Achieved Positive Results from Mutual Project with Fortune 500 Automotive Manufacturer
Published: 2024-01-29 (Crawled : 12:30) - globenewswire.com
PRZO | $0.736 -9.73% -10.77% 870K
|
n/a
|
| O: 5.19%
H: 7.01%
C: -0.12%
fortune positive automotive 500 results
Acurx Announces Positive Extended Clinical Cure Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients
Published: 2024-01-29 (Crawled : 12:00) - prnewswire.com
ACXP | $2.11 17.22% 14.69% 140K
|
Professional, Scientific, and T...
|
| O: 0.26%
H: 1.55%
C: -5.15%
cure positive ibezapolstat trial
ENHERTU® Granted Priority Review in the U.S. for Patients with Metastatic HER2 Positive Solid Tumors
Published: 2024-01-29 (Crawled : 11:00) - biospace.com/
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: 0.24%
H: 0.07%
C: -0.1%
enhertu her2 granted review tumors positive
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
Published: 2024-01-29 (Crawled : 09:00) - globenewswire.com
ALVO | $12.9 0.78% 0.78% 90K
|
n/a
|
| O: 2.39%
H: 4.67%
C: 1.67%
KMDA | $5.075 -0.1% -0.1% 6.5K
|
Health Technology
|
| O: -1.05%
H: 0.41%
C: -0.35%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: -0.11%
H: 0.7%
C: 0.65%
avt03 prolia biosimilar positive results study
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
Published: 2024-01-26 (Crawled : 15:30) - biospace.com/
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: 0.71%
H: 0.48%
C: -0.52%
chmp positive cell therapy
CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024
Published: 2024-01-26 (Crawled : 12:30) - globenewswire.com
CRBP | $36.465 -1.87% -1.91% 130K
|
Health Technology
|
| O: 98.82%
H: 0.0%
C: 0.0%
crb-701 drug antibody tumors positive study
Tonix Pharmaceuticals Announces KOL Webinar to Discuss Positive Phase 3 Fibromyalgia Data, Sponsored by A.G.P.
Published: 2024-01-25 (Crawled : 12:00) - globenewswire.com
TNXP | $0.1549 -2.82% -2.91% 1.4M
|
Health Technology
|
| O: 5.14%
H: 4.32%
C: 4.22%
fibromyalgia positive pharmaceuticals
Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy
Published: 2024-01-25 (Crawled : 12:00) - globenewswire.com
VERA | $39.51 -1.25% -1.27% 860K
|
Professional, Scientific, and T...
|
| O: 30.79%
H: 19.79%
C: 13.7%
nephropathy origin positive trial therapeutics
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.